Alnylam Pharmaceuticals, Inc. (ALNY) — Form SCHEDULE 13G/A: Ownership over 5% (passive) (amendment)

Capital World Investors filed an amended Schedule 13G/A reporting beneficial ownership of 13,934,539 shares of Common Stock of Alnylam Pharmaceuticals, Inc. This stake represents 10.4% of the company's outstanding shares as of 09/30/2026. The filing indicates the securities are held in the ordinary course of business without the purpose of changing or influencing control.